CONMED Corporation (CNMD)

Return on equity (ROE)

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Net income (ttm) US$ in thousands 64,071 110,196 118,751 132,424 131,740 98,593 82,349 64,459 57,972 88,285 -93,738 -80,582 -82,722 -113,924 67,657 62,542 62,238 54,140 13,450 9,517
Total stockholders’ equity US$ in thousands 1,008,260 1,002,870 977,636 962,681 932,896 881,832 854,664 834,222 796,205 780,194 752,453 745,545 716,337 672,968 789,546 785,435 755,683 744,499 725,570 709,038
ROE 6.35% 10.99% 12.15% 13.76% 14.12% 11.18% 9.64% 7.73% 7.28% 11.32% -12.46% -10.81% -11.55% -16.93% 8.57% 7.96% 8.24% 7.27% 1.85% 1.34%

September 30, 2025 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $64,071K ÷ $1,008,260K
= 6.35%


Peer comparison

Sep 30, 2025

Company name
Symbol
ROE
CONMED Corporation
CNMD
6.35%
Abbott Laboratories
ABT
27.43%
Stryker Corporation
SYK
14.48%